
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Gilead Sciences (United Kingdom), United Kingdom, covering academic research published from 2001 to 2024. Read More.
Open Access Percentage
63%
Total
Publications
253
Total Open
Publications
160
Total
Citations
5.8K
Open Access
Percentage
63%
Total
Publications
253
Total Open
Publications
160
Total
Citations
5.8K
Breakdown
Publisher Open
24%
Both
33%
Other Platform Open
6%
Closed
37%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 45%
65
Hybrid 32%
45
No Guarantees 23%
33
Other Platform Open
Domain 86%
83
Institution 32%
31
Other Internet 6%
6
Preprint 2%
2
Public 1%
1
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 85 |
DOI | Other Internet | 6 |
RISalud Institutional Health Repository of Andalucía | Institution | 5 |
University of Milano-Bicocca - BOA | Institution | 4 |
Le Centre pour la Communication Scientifique Directe - HAL - Diderot | Institution | 3 |
Imperial College London - Spiral | Institution | 3 |
University of Udine - Institutional Research Information System | Institution | 2 |
University of Groningen / Centre for Information Technology - University of Groningen research database | Institution | 2 |
University of Dundee - Discovery Research Portal | Institution | 2 |
University of Bristol - Bristol Research | Institution | 2 |